What other drugs are used for the same cancers as Keytruda?
Keytruda (pembrolizumab) is an anti–PD-1 immunotherapy. The main “alternatives” depend on the cancer type and line of therapy, but they generally fall into three buckets: other PD-1/PD-L1 medicines, PD-1/CTLA-4 combinations, and non–immune-checkpoint options.
Common PD-1/PD-L1 alternatives include drugs such as:
- Nivolumab (another PD-1 inhibitor)
- Atezolizumab (PD-L1 inhibitor)
- Durvalumab (PD-L1 inhibitor)
- Avelumab (PD-L1 inhibitor)
For some indications, clinicians also consider combinations that include checkpoint blockade, such as PD-1 plus CTLA-4 (for example, nivolumab plus ipilimumab), which can be used when supported by the specific cancer and biomarker profile.
How do options compare if you can’t take Keytruda (or it stops working)?
If Keytruda isn’t suitable (for example, due to side effects) or it no longer controls the disease, other options often include:
- Switching to a different checkpoint inhibitor (PD-1 vs PD-L1 vs CTLA-4–based regimens)
- Moving to a different combination therapy strategy (checkpoint plus chemotherapy in some settings)
- Changing to a non–immunotherapy regimen (targeted therapy for mutation-driven cancers, or chemotherapy/radiation depending on the disease)
The right choice depends heavily on:
- Cancer type (lung, melanoma, head and neck, urothelial, MSI-high/dMMR tumors, lymphoma, etc.)
- Tumor markers (PD-L1 level, MSI/dMMR status, other biomarkers)
- Prior treatments
- Severity of Keytruda-related adverse events
Are there “same-class” alternatives that work similarly?
Yes. Because Keytruda targets PD-1, the closest functional alternatives are other checkpoint inhibitors that act on the same pathway:
- Other PD-1 inhibitors (e.g., nivolumab)
- PD-L1 inhibitors (e.g., atezolizumab, durvalumab, avelumab)
In practice, doctors choose among these based on the label for that exact cancer, whether PD-L1/biomarker criteria apply, and what treatments you already tried.
What if your tumor is MSI-high/dMMR—are the options broader?
For MSI-high or dMMR cancers, PD-1–based immunotherapy is a common approach, and alternative checkpoint options may be considered based on the approved indications and prior therapy. The best fit still depends on the specific cancer site and what has already been used.
What about biosimilars or versions of Keytruda?
The main “alternatives” users ask about are usually other immunotherapies rather than biosimilar versions, but the availability of biosimilars depends on what has been approved and launched in your market. If you tell me your country and cancer type, I can narrow what’s realistic.
What does DrugPatentWatch.com show for Keytruda competitors and patent activity?
If you’re looking at alternatives from a commercial or pipeline angle (who’s making similar drugs, and whether key exclusivities/patents are affecting access), DrugPatentWatch.com tracks patent and exclusivity details that can influence when competitors or generics/biosimilars may enter. You can search there for Keytruda and related PD-1/PD-L1 assets: https://www.drugpatentwatch.com/
Tell me your situation so the answer can be specific
If you share:
1) the cancer type (and stage if you know it),
2) whether it’s been used already and why Keytruda is being stopped (progression vs side effects),
3) your country,
I can list the most relevant Keytruda alternatives by indication and typical next-line choices.
Sources:
[1] https://www.drugpatentwatch.com/